Overall assessment of the factors influencing the effect of anti-vascular endothelial growth factor for neovascular age-related macular degeneration to improve the comprehensive benefit of treatment_Chinese Journal of Ocular Fundus Diseases

Authors：

 DaiHong , LuYingyi

Department of Ophthalmology, Beijing Hospital, Beijing 100730;

Corresponding author：

DaiHong, Email: dai-hong@x263.net

Keywords：

Wet macular degeneration/drug therapy; Choroidal neovascularization/drug therapy; Angiogenesis inhibitors/therapeutic use; Antibodies, monoclonal/therapeutic use; Editorial

DOI：

10.3760/cma.j.issn.1005-1015.2016.01.003

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The therapeutic effect of anti-vascular endothelial growth factor (VEGF) for neovascular age-related macular degeneration (nAMD) was determined by a number of factors. Comprehensive thorough analysis of clinical features, imaging results and treatment response can predict the potential efficacy and possible vision recovery for the patient, and also can optimize the treatment regime to make a personalized therapy plan. Precise medicine with data from genomics, proteomics and metabolomics study will provide more objective and accurate biology basis for individual precise treatment. The future research should focus on comprehensive assessment of factors affecting the efficacy of anti-VEGF therapy, to achieve individualized precise diagnosis and treatment, to improve the therapeutic outcome of nAMD.

Citation： DaiHong, LuYingyi. Overall assessment of the factors influencing the effect of anti-vascular endothelial growth factor for neovascular age-related macular degeneration to improve the comprehensive benefit of treatment. Chinese Journal of Ocular Fundus Diseases, 2016, 32(1): 8-11. doi: 10.3760/cma.j.issn.1005-1015.2016.01.003 Copy

1.	中华医学会眼科学分会眼底病学组中国老年性黄斑变性临床指南与临床路径制定委员会.中国老年性黄斑变性临床诊断治疗路径[J].中华眼底病杂志, 2013, 29 (4): 343-355. DOI: 10.3760/cma.j.issn.1005-1015.2013.04.002.The Clinical Guideline and Clinical Pathway Development Committee of Age Related Macular Degeneration, Ocular Fundus Diseases Society, Chinese Ophthalmological Society, hinese Medical Association.Clinical pathway of age-related macular degeneration in China[J].Chin J Ocul Fundus Dis, 2013, 29 (4): 343-355. DOI: 10.3760/cma.j.issn.1005-1015.2013.04.002.
2.	Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP) [J]. Ophthalmology, 2013, 120(11):2292-2299. DOI:10.1016/j.ophtha.2013.03.046.
3.	戴虹, 喻晓兵, 龙力, 等.抗血管内皮生长因子单克隆抗体ranibizumab治疗渗出型老年性黄斑变性方案的探讨[J].中华眼底病杂志, 2010, 26(1):9-12.DOI:10.3760/cma.j.issn.1005-1015.2010.01.03.Dai H, Yu XB, Long L, et al. Intravitreal ranibizumab regimens for exudative aged-related macular degeneration [J]. Chin J Ocul Fundus Dis, 2010, 26(1):9-12.DOI:10.3760/cma.j.issn.1005-1015.2010.01.03.
4.	戴虹.抗血管内皮生长因子药物治疗脉络膜新生血管疾病临床研究应注意的几个问题[J].中华眼底病杂志, 2011, 27:503-505. DOI: 10.3760/cma.j.issn.1005-1015.2011.06.001.Dai H. Issues raised in clinical researches using anti-vascular endothelial growth factor drugs to treat choroidal neovascularization[J]. Chin J Ocul Fundus Dis, 2011, 27(6):503-505.DOI: 10.3760/cma.j.issn.1005-1015.2011.06.001.
5.	Dedania VS, Grob S, Zhang K, et al. Pharmacogenomics of response to anti-VEGF therapy in exudative age-related macular degeneration[J]. Retina, 2015, 35(3):381-391. DOI:10.1097/IAE.
6.	戚沆, 陈长征.影响渗出型老年性黄斑变性患者玻璃体腔注射雷珠单抗治疗反应的临床特征与基因因素[J].中华眼底病杂志, 2015, 31(1):95-97.DOI:10.3760/cma.j.issn.1005-1015.2015.01.027.Qi H, Chen CZ. Clinical features and genetic factors influencing the effect of intravitreal ranibizumab for exudative age-related macular degeneration[J].Chin J Ocul Fundus Dis, 2015, 31(1):95-97.DOI:10.3760/cma.j.issn.1005-1015.2015.01.027.
7.	Chae B, Jung JJ, Mrejen S, et al. Baseline predictors for good versus poor visual outcomes in the treatment of neovascular age-related macular degeneration with intravitreal anti-VEGF therapy [J]. Invest Ophthalmol Vis Sci, 2015, 56(9):5040-5047. DOI: 10.1167/iovs.15-16494.
8.	Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration [J]. Ophthalmology, 2013, 120(1):122-129. DOI: 10.1016/j.ophtha.2012.07.042.
9.	Rasmussen A, Brandi S, Fuchs J, et al. Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration[J]. Acta Ophthalmol, 2015, 93(7):616-620. DOI: 10.1111/aos.12781.
10.	Kuroda Y, Yamashiro K, Tsujikawa A, et al. Retinal pigment epithelial atrophy in neovascular age-related macular degeneration after ranibizumab treatment [J]. Am J Ophthalmol, 2016, 161:94-103. DOI: 10.1016/j.ajo.2015.09.032.
11.	Wickremasinghe SS, Sandhu SS, Busija L, et al. Predictors of AMD treatment response [J]. Ophthalmology, 2012, 119(11):2413-2414. DOI: 10.1016/j.ophtha.2012.06.056.
12.	Ebneter A, Gekkiev B, Chanana B, et al. The presence of intra-or subretinal fluid during the loading phase in the treatment of exudative age-related macular degeneration with intravitreal ranibizumab assessed by optical coherence tomography[J]. Ophthalmologica, 2015, 234(2):61-66. DOI: 10.1159/000430103.
13.	Lee JY, Folgar FA, Maguire MG, et al. Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT) [J]. Ophthalmology, 2014, 121(12):2423-2431. DOI: 10.1016/j.ophtha.2014.06.013.
14.	Pron G. Optical coherence tomography monitoring strategies for a-VEGF-treated age-related macular degeneration: an evidence-based analysis [J]. Ont Health Technol Assess Ser, 2014, 14(10):1-64.
15.	Puliafito CA. OCT angiography: the next era of oct technology emerges [J]. Ophthalmic Surg Lasers Imaging Retina, 2014, 45(5):360. DOI: 10.3928/23258160-20140925-01.
16.	Heimes B, Lommatzsch A, Zeimer M, et al. Foveal RPE autofluorescence as a prognostic factor for anti-VEGF therapy in exudative AMD [J]. Graefe's Arch Clin Exp Ophthalmol, 2008, 246(9):1229-1234. DOI: 10.1007/s00417-008-0854-z.
17.	Ying GS, Maguire MG, Daniel E, et al. Association of baseline characteristics and early vision response with 2-year vision outcomes in the comparison of AMD treatments trials (CATT) [J]. Ophthalmology, 2015, 122(12):2523-2531. DOI: 10.1016/j.ophtha.2015.08.015.
18.	Mrejen S, Jung JJ, Chen C, et al. Long-term visual outcomes for a treat and extend anti-vascular endothelial growth factor regimen in eyes with neovascular age-related macular degeneration[J]. J Clin Med, 2015, 4(7):1380-1402. DOI: 10.3390/jcm4071380.
19.	Homer N, Grewal DS, Mirza RG, et al. Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results[J]. Eye, 2015, 29(12):1152-1155. DOI: 10.1038/eye.2015.87.

1. 中华医学会眼科学分会眼底病学组中国老年性黄斑变性临床指南与临床路径制定委员会.中国老年性黄斑变性临床诊断治疗路径[J].中华眼底病杂志, 2013, 29 (4): 343-355. DOI: 10.3760/cma.j.issn.1005-1015.2013.04.002.The Clinical Guideline and Clinical Pathway Development Committee of Age Related Macular Degeneration, Ocular Fundus Diseases Society, Chinese Ophthalmological Society, hinese Medical Association.Clinical pathway of age-related macular degeneration in China[J].Chin J Ocul Fundus Dis, 2013, 29 (4): 343-355. DOI: 10.3760/cma.j.issn.1005-1015.2013.04.002.
2. Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP) [J]. Ophthalmology, 2013, 120(11):2292-2299. DOI:10.1016/j.ophtha.2013.03.046.
3. 戴虹, 喻晓兵, 龙力, 等.抗血管内皮生长因子单克隆抗体ranibizumab治疗渗出型老年性黄斑变性方案的探讨[J].中华眼底病杂志, 2010, 26(1):9-12.DOI:10.3760/cma.j.issn.1005-1015.2010.01.03.Dai H, Yu XB, Long L, et al. Intravitreal ranibizumab regimens for exudative aged-related macular degeneration [J]. Chin J Ocul Fundus Dis, 2010, 26(1):9-12.DOI:10.3760/cma.j.issn.1005-1015.2010.01.03.
4. 戴虹.抗血管内皮生长因子药物治疗脉络膜新生血管疾病临床研究应注意的几个问题[J].中华眼底病杂志, 2011, 27:503-505. DOI: 10.3760/cma.j.issn.1005-1015.2011.06.001.Dai H. Issues raised in clinical researches using anti-vascular endothelial growth factor drugs to treat choroidal neovascularization[J]. Chin J Ocul Fundus Dis, 2011, 27(6):503-505.DOI: 10.3760/cma.j.issn.1005-1015.2011.06.001.
5. Dedania VS, Grob S, Zhang K, et al. Pharmacogenomics of response to anti-VEGF therapy in exudative age-related macular degeneration[J]. Retina, 2015, 35(3):381-391. DOI:10.1097/IAE.
6. 戚沆, 陈长征.影响渗出型老年性黄斑变性患者玻璃体腔注射雷珠单抗治疗反应的临床特征与基因因素[J].中华眼底病杂志, 2015, 31(1):95-97.DOI:10.3760/cma.j.issn.1005-1015.2015.01.027.Qi H, Chen CZ. Clinical features and genetic factors influencing the effect of intravitreal ranibizumab for exudative age-related macular degeneration[J].Chin J Ocul Fundus Dis, 2015, 31(1):95-97.DOI:10.3760/cma.j.issn.1005-1015.2015.01.027.
7. Chae B, Jung JJ, Mrejen S, et al. Baseline predictors for good versus poor visual outcomes in the treatment of neovascular age-related macular degeneration with intravitreal anti-VEGF therapy [J]. Invest Ophthalmol Vis Sci, 2015, 56(9):5040-5047. DOI: 10.1167/iovs.15-16494.
8. Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration [J]. Ophthalmology, 2013, 120(1):122-129. DOI: 10.1016/j.ophtha.2012.07.042.
9. Rasmussen A, Brandi S, Fuchs J, et al. Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration[J]. Acta Ophthalmol, 2015, 93(7):616-620. DOI: 10.1111/aos.12781.
10. Kuroda Y, Yamashiro K, Tsujikawa A, et al. Retinal pigment epithelial atrophy in neovascular age-related macular degeneration after ranibizumab treatment [J]. Am J Ophthalmol, 2016, 161:94-103. DOI: 10.1016/j.ajo.2015.09.032.
11. Wickremasinghe SS, Sandhu SS, Busija L, et al. Predictors of AMD treatment response [J]. Ophthalmology, 2012, 119(11):2413-2414. DOI: 10.1016/j.ophtha.2012.06.056.
12. Ebneter A, Gekkiev B, Chanana B, et al. The presence of intra-or subretinal fluid during the loading phase in the treatment of exudative age-related macular degeneration with intravitreal ranibizumab assessed by optical coherence tomography[J]. Ophthalmologica, 2015, 234(2):61-66. DOI: 10.1159/000430103.
13. Lee JY, Folgar FA, Maguire MG, et al. Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT) [J]. Ophthalmology, 2014, 121(12):2423-2431. DOI: 10.1016/j.ophtha.2014.06.013.
14. Pron G. Optical coherence tomography monitoring strategies for a-VEGF-treated age-related macular degeneration: an evidence-based analysis [J]. Ont Health Technol Assess Ser, 2014, 14(10):1-64.
15. Puliafito CA. OCT angiography: the next era of oct technology emerges [J]. Ophthalmic Surg Lasers Imaging Retina, 2014, 45(5):360. DOI: 10.3928/23258160-20140925-01.
16. Heimes B, Lommatzsch A, Zeimer M, et al. Foveal RPE autofluorescence as a prognostic factor for anti-VEGF therapy in exudative AMD [J]. Graefe's Arch Clin Exp Ophthalmol, 2008, 246(9):1229-1234. DOI: 10.1007/s00417-008-0854-z.
17. Ying GS, Maguire MG, Daniel E, et al. Association of baseline characteristics and early vision response with 2-year vision outcomes in the comparison of AMD treatments trials (CATT) [J]. Ophthalmology, 2015, 122(12):2523-2531. DOI: 10.1016/j.ophtha.2015.08.015.
18. Mrejen S, Jung JJ, Chen C, et al. Long-term visual outcomes for a treat and extend anti-vascular endothelial growth factor regimen in eyes with neovascular age-related macular degeneration[J]. J Clin Med, 2015, 4(7):1380-1402. DOI: 10.3390/jcm4071380.
19. Homer N, Grewal DS, Mirza RG, et al. Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results[J]. Eye, 2015, 29(12):1152-1155. DOI: 10.1038/eye.2015.87.

Chinese Journal of Ocular Fundus Diseases

Overall assessment of the factors influencing the effect of anti-vascular endothelial growth factor for neovascular age-related macular degeneration to improve the comprehensive benefit of treatment

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content